Please login to the form below

Not currently logged in
Email:
Password:

nabiximols

This page shows the latest nabiximols news and features for those working in and with pharma, biotech and healthcare.

NICE denies two drugs in new MS guidance

NICE denies two drugs in new MS guidance

The National Institute for Health and Care Excellence (NICE) did not recommend the use of GWPharma's Sativex (nabiximols), which is derived from the cannabis plant, or Biogen Idec's Fampyra

Latest news

  • Cancer pain: opioids set to dominate Cancer pain: opioids set to dominate

    Phase III: opioid agonists. GW Pharmaceuticals has developed a buccal spray known as nabiximols or Sativex, which comprises delta-9-tetrahydrocannabinol (27mg/mL) and cannabidiol (25mg/mL), as an analgesic agent

  • Glioblastomas - a personalised future? Glioblastomas - a personalised future?

    Also of note, the buccal spray nabiximols - an analgesic combination of delta-9-tetrahydrocannabinol and cannabidiol marketed for treatment of cancer and neuropathic pain and muscle spasticity, and the first cannabinoid ... Nabiximols inhibits glioma

  • Almirall expands in US via $400m deal to buy Aqua Almirall expands in US via $400m deal to buy Aqua

    under 22m on the back of high roll-out costs for new products such as Sativex (nabiximols) for spasticity in multiple sclerosis (MS) and chronic obstructive pulmonary disorder (COPD) treatment Eklira

  • Almirall launches Sativex in Italy Almirall launches Sativex in Italy

    Sativex (nabiximols) is licensed to treat moderate to severe spasticity in MS patients who have not responded adequately to other anti-spasticity medication and will be reimbursed by the Italian authorities

  • GW Pharma says German Sativex pricing GW Pharma says German Sativex pricing "unacceptable"

    Sativex (nabiximols) is an oromucosal spray containing active ingredients from the cannabis sativa plant used to treat moderate to severe spasticity in multiple sclerosis patients who have not responded to other

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics